Cancer Epidemiology
Volume 34, Issue 3 , Pages 257-261 , June 2010

The impact of Kaposi sarcoma and non-Hodgkin lymphoma on mortality of people with AIDS in the highly active antiretroviral therapies era

  • Diego Serraino

      Affiliations

    • Unit of Epidemiology and Biostatistics, Centro di Riferimento Oncologico, IRCCS, Via F. Gallini, 2, 33081 Aviano (PN), Italy
    • Corresponding Author InformationCorresponding author. Fax: +39 0434 659 231.
    • ,
  • Angela De Paoli

      Affiliations

    • Unit of Epidemiology and Biostatistics, Centro di Riferimento Oncologico, IRCCS, Via F. Gallini, 2, 33081 Aviano (PN), Italy
    • ,
  • Antonella Zucchetto

      Affiliations

    • Unit of Epidemiology and Biostatistics, Centro di Riferimento Oncologico, IRCCS, Via F. Gallini, 2, 33081 Aviano (PN), Italy
    • ,
  • Simona Pennazza

      Affiliations

    • Direzione centrale per le statistiche e le indagini sulle istituzioni sociali, Servizio Sanità e Assistenza ISTAT, Roma, Italy
    • ,
  • Silvia Bruzzone

      Affiliations

    • Direzione centrale per le statistiche e le indagini sulle istituzioni sociali, Servizio Sanità e Assistenza ISTAT, Roma, Italy
    • ,
  • Michele Spina

      Affiliations

    • Medical Oncology Division, Centro di Riferimento Oncologico, IRCCS, Aviano, Italy
    • ,
  • Paolo De Paoli

      Affiliations

    • Scientific Direction, Centro di Riferimento Oncologico, IRCCS, Aviano, Italy
    • ,
  • Giovanni Rezza

      Affiliations

    • Dipartimento di Malattie Infettive, Centro Operativo AIDS, Istituto Superiore di Sanità, Roma, Italy
    • ,
  • Luigino Dal Maso

      Affiliations

    • Unit of Epidemiology and Biostatistics, Centro di Riferimento Oncologico, IRCCS, Via F. Gallini, 2, 33081 Aviano (PN), Italy
    • ,
  • Barbara Suligoi

      Affiliations

    • Dipartimento di Malattie Infettive, Centro Operativo AIDS, Istituto Superiore di Sanità, Roma, Italy

,Accepted 23 March 2010.

References 

  1. Franceschi S, Dal Maso L, Rickenbach M, Polesel J, Hirschel B, Cavassini M, et al. Kaposi sarcoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. Br J Cancer. 2008;99:800–804
  2. Polesel J, Clifford GM, Rickenbach M, Dal Maso L, Battegay M, Bouchardy C, et al. Non-Hodgkin lymphoma incidence in the Swiss HIV cohort study before an after highly active antiretroviral therapy. AIDS. 2008;22:301–306
  3. Mocroft A, Kirk O, Clumeck N, Gargalianos-Kakolyris P, Trocha H, Chentsova N, et al. The changing pattern of Kaposi sarcoma in patients with HIV, 1994–2003. Cancer. 2004;100:2644–2654
  4. Kirk O, Pedersen C, Cozzi-Lepri A, Antunes F, Miller V, Gatell JM, et al. Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy. Blood. 2001;98:3406–3412
  5. Serraino D, Piselli P, Busnach G, Burra P, Citterio F, Arbustini E, et al. Risk of cancer following immune suppression in organ transplant recipients and HIV-positive individuals in southern Europe. Eur J Cancer. 2007;43:2117–2123
  6. Dal Maso L, Polesel J, Serraino D, Lise M, Piselli P, Falcini F, et al. Pattern of cancer risk in persons with AIDS in Italy in the HAART era. Br J Cancer. 2009;100:840–847
  7. Biggar RJ, Engels EA, Ly S, Kahn A, Schymura MJ, Sackoff J, et al. Survival after cancer diagnosis in persons with AIDS. J Acquir Immune Defic Syndr. 2005;39:293–299
  8. Vaccher E, Spina M, Talamini R, Zanetti M, Di Gennaro G, Nasti G, et al. Improvement of systemic human immunodeficiency virus-related non-Hodgkin lymphoma out come in the era of highly active antiretroviral therapy. Clin Infect Dis. 2003;37:1556–1564
  9. Mounier N, Spina M, Gabarre J, Raphael M, Rizzardini G, Golfier JB, et al. AIDS-related non-Hodgkin lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy. Blood. 2006;107:3832–3840
  10. Du Pont C, Vasseur E, Beauchet A, Aegerter P, Berthé H, de Truchis P, et al. Long-term efficacy on Kaposi's sarcoma of highly active antiretroviral therapy in a cohort of HIV-positive patients. CISIH 92. Centre d’information et de soins de l’immunodéficience humaine. AIDS. 2000;14:987–993
  11. Selik RM, Byer RH, Dworkin MS. Trends in diseases reported on U.S. death certificates that mentioned HIV infection, 1987–1999. J Acquir Immune Defic Syndr. 2002;29:378–387
  12. Hooshyar D, Hanson DL, Wolfe M, Selik RM, Buskin SE, McNaghten AD. Trends in perimortal conditions and mortality rates among HIV-infected patients. AIDS. 2002;21:2093–2100
  13. Serraino D, Zucchetto A, Suligoi B, Bruzzone S, Camoni L, Boros S, et al. Survival after AIDS diagnosis in Italy, 1999–2006: a population-based study. J Acquir Immune Defic Syndr. 2009;51:99–102
  14. Ancelle Park RA. Expanded European AIDS case definition. Lancet. 1993;341:441
  15. Conti S, Masocco M, Pezzotti P, Toccaceli V, Vichi M, Boros S, et al. Differential impact of combined antiretroviral therapy on the survival of Italian patients with specific AIDS-defining illnesses. J Acquir Immune Defic Syndr. 2000;25:451–458
  16. Pezzotti P, Napoli PA, Acciai S, Boros S, Urciuoli R, Lazzeri V, et al. Increasing survival time after AIDS in Italy: the role of new combination antiretroviral therapies. AIDS. 1999;13:249–255
  17. Conti S, Farchi G, Galletti A, Masocco M, Napoli PA, Pezzotti P, et al. La notifica della mortalità per AIDS in Italia (1992): qualità della certificazione e sottonotifica. Giornale italiano dell’AIDS. 1997;8:12–16
  18. Breslow NE, Day NE. Statistical methods in cancer research. Volume II–The design and analysis of cohort studies. IARC Sc. Pub. No. 82. Lyon: International agency for research on cancer; 1987;
  19. Spina M, Carbone A, Vaccher E, Gloghini A, Talamini R, Cinelli R, et al. Outcome in patients with non-Hodgkin lymphoma and with or without human immunodeficiency virus infection. Clin Infect Dis. 2004;38:142–144
  20. Spina M, Jaeger U, Sparano JA, Talamini R, Simonelli C, Michieli M, et al. Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide (R-CDE) in HIV-associated non-Hodgkin's lymphoma: pooled results from three phase II trials. Blood. 2005;105:1891–1897
  21. Re A, Michieli M, Casari S, Allione B, Cattaneo C, Rupolo M, et al. High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: long-term results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study with analysis of prognostic factors. Blood. 2009;114:1306–1313
  22. Chadborn TR, Delpech VC, Sabin CA, Sinka K, Evans BG. The late diagnosis and consequent short-term mortality of HIV-infected heterosexuals (England and Wales, 2000–2004). AIDS. 2006;20:2371–2379
  23. Valdez H, Chowdhry TK, Asaad R, Woolley IJ, Davis T, Davidson R, et al. Changing spectrum of mortality due to human immunodeficiency virus: analysis of 260 deaths during 1995–1999. Clin Infect Dis. 2001;32:1487–1493
  24. French AL, Gawel SH, Hershow R, Benning L, Hessol NA, Levine AM, et al. Trends in mortality and causes of death among women with HIV in the United States: a 10-year study. J Acquir Immune Defic Syndr. 2009;51:399–406
  25. Louie JK, Hsu LC, Osmond DH, Katz MH, Schwarcz SK. Trends in causes of death among persons with acquired immunodeficiency syndrome in the era of highly active antiretroviral therapy, San Francisco, 1994–1998. J Infect Dis. 2002;186:1023–1027
  26. Pacheco AG, Tuboi SH, May SB, Moreira LF, Ramadas L, Nunes EP, et al. Temporal changes in cause of death among HIV-infected patients in the HAART era in Rio de Janeiro, Brazil. J Acquir Immune Defic Syndr. 2009;51:624–630
  27. Selik RM, Rabkin CS. Cancer death rates associated with human immunodeficiency virus infection in the United States. J Natl Cancer Inst. 1998;90:1300–1302

PII: S1877-7821(10)00051-2

doi: 10.1016/j.canep.2010.03.011

Cancer Epidemiology
Volume 34, Issue 3 , Pages 257-261 , June 2010

Article Tools

* Image Usage & Resolution